Melanotan-2 Prices

This is the one monograph where the risks deserve top billing rather than a footnote. MT-II directly stimulates the melanocytes implicated in melanoma, and there are real published case reports, plus formal government warnings, of melanoma and changing moles during use. It also causes priapism, a genuine medical emergency. Its underlying science is legitimate (it spawned an FDA-approved drug), but MT-II itself is unapproved, banned in sport, and unregulated. Everything below is research context, not medical advice, and the safety section matters more here than usual.

Key research takeaways

Melanotan-2 at a glance

Documented serious harms: peer-reviewed melanoma/eruptive-nevi case reports with formal MHRA and TGA safety warnings, plus priapism (a urological emergency). Directly stimulates melanocytes. Nausea and flushing are common. Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.

Study highlights

• Synthetic cyclic α-MSH analog that binds MC1R, MC3R, MC4R and MC5R, the broad receptor profile is what drives both the tanning response (MC1R → tyrosinase → eumelanin) and the central pro-erectile/anorexic effects (MC4R in the hypothalamus), and is also why side effects cluster across so many systems.
• Originally developed at the University of Arizona in the 1980s for UV-sparing skin photoprotection in patients at high melanoma risk; Dorr et al. 1996 (Life Sciences) showed dose-dependent tanning in a Phase I trial, and Wessells 1998 (J Urology) demonstrated improved erections in men with psychogenic erectile dysfunction.
• Safety signal that limits clinical translation: multiple case reports in the British Journal of Dermatology have described eruptive nevi, mole darkening, and melanoma diagnosed during or shortly after unregulated Melanotan-2 use, driving formal warnings from the UK MHRA and Australia's TGA against import and sale.

Selected references

1. Evaluation of Melanotan-II, a Superpotent Cyclic Melanotropic Peptide, in a Phase I Clinical Trial · Life Sciences, 1996
2. Synthetic Melanotropic Peptide Initiates Erections in Men with Psychogenic Erectile Dysfunction · Journal of Urology, 1998
3. Melanoma Associated with the Use of Melanotan-II · British Journal of Dermatology, 2009
4. MHRA Response on Melanotan II Product Status and Adverse Reaction Reports · UK MHRA, 2024
5. Don't Risk Using Tanning Products Containing Melanotan · Australia TGA, 2025